Phases I–III Clinical Trials Using Adult Stem Cells

Table 3

Randomized clinical trials in patients with chronic ischemic heart failure.

Trial	$N$	Cell type	Delivery	Timing	Primary endpoint	Comments
MAGIC [21]	97	SM	transepi	$>$4 weeks	No change LVEF	Reduction in LVEDV/LVESV
Dib [22]	23	SM	transendo	$>$10 years	Improved LVEF and viability	—
SEISMIC	47	SM	transendo	chronic	No change LVEF	—
TOPCARE-CHD [23]	58	BMMC versus CPC	ic	81 $\pm$ 72 months	Improved LVEF w/BMMC	—

SM: skeletal myoblasts; BMMC: bone marrow mononuclear cells; CPC: circulating progenitor cells; transepi: tranepicardial; transendo: transendocardial; ic: intracoronary; LVEF: left ventricular ejection fraction; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume.